Puncturing the Orphan Drug Bubble
This article was originally published in RPM Report
BioMarin’s investor day highlighted a company in transformation: on the brink of profitability based on a stable of rare disease therapies, and generating buzz for an early stage research compound in oncology. Balancing those two portfolios may be challenging – and framing appeals to investors may be counterproductive in protecting the orphan drug model.
You may also be interested in...
Two former biotech high flyers are up for sale, with Amylin attracting more would-be suitors than Human Genome Sciences. The spectacle of the bidding is great. But did you know that the orphan drug company Alexion is worth more than those two companies combined?
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.